Alteogen Inc. Alteogen Inc.

Alteogen Inc.

196170

주식 순위 #1844
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
주가
$165.61
시가총액
$11.53B
변동 (1일)
4.13%
변동 (1년)
-46.48%
국가
KR
거래 Alteogen Inc. (196170)

카테고리

Healthcare
Alteogen Inc. (196170)의 주식 분할 이력
Alteogen Inc. 주식 (심볼: 196170)은 총 5회의 주식 분할을 거쳤습니다.
가장 최근의 분할은 Aug 05, 2026에 발생했습니다.
Dec 07, 2017 이전에 매수한 196170 주식 1주는 현재 1.2037037037037주의 196170 주식에 해당합니다.
주식 분할 목록
연도 주식 분할 배수 누적 배수
2026-08-05 13:10 x1.3 x1.2037037037037
2022-10-25 6:5 x1.2 x0.92592592592593
2021-03-24 5:4 x1.25 x0.77160493827161
2020-07-23 10:9 x1.1111111111111 x0.61728395061728
2017-12-07 5:9 x0.55555555555556 x0.55555555555556
유사 기업 또는 경쟁사의 주식 분할
회사 주식 분할 횟수 누적 배수 국가
1 x2
US
0 -
US
1 x3
AU
0 -
CH
0 -
NL